Atsena Reports Early XLRS Gene-Therapy Signal

Company Atsena Therapeutics Event Type Preliminary clinical data Modality AAV gene therapy (subretinal; AAV.SPR capsid) Asset ATSN-201 Target RS1 (retinoschisin) gene replacement Disease Area X-linked retinoschisis Summary Atsena reported preliminary Phase I/II/III LIGHTHOUSE data for ATSN-201 in X-linked retinoschisis, including functional and anatomical responses at…